Back
ESC2025 Premium Access

Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis

Session: Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?
Topic: Antidiabetic Pharmacotherapy
Speaker: Professor S. Mulvagh (Halifax, CA)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Sharon Mulvagh

Dalhousie University, Halifax (Canada)
4 presentations
1 follower

4 more presentations in this session

State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

Speaker: Professor D. Bhatt (New York, US)

Access
Slides
Video
Like
Thumbnail

Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF

Speaker: Doctor R. Aggarwal (Boston, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Undertreatment of women with lipid-lowering therapies in four European countries: results from the prospective, non-interventional MILOS Study

Speaker: Professor I. Gouni-Berthold (Cologne, DE)

Access
Abstract
Slides
Video
Like
Thumbnail

Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT

Speaker: Doctor D. Bhatt (New York, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

Speakers: Professor S. Mulvagh, Professor D. Bhatt, Doctor R. Aggarwal, Professor I. Gouni-Berthold, Doctor D. Bhatt
Access
Video
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources